Altiratinib
Altiratinib (DCC-2701) is a multi-kinase inhibitor targeting c-MET, TIE-2, and VEGFR. It has been shown to inhibit c-MET phosphorylation, cell proliferation, and migration in vitro, and demonstrates efficacy in reducing tumor growth in vivo, supporting its investigation in oncology research.
Product Specifications
CAS Number
1345847-93-9
Product Name Alternative
Tie2, Tie-2, Trkreceptor, Tropomyosin related kinase receptor, Trk receptor, Trk Receptor, TrkA, TrkC, Vascular endothelial growth factor receptor, VEGFR, Inhibitor, HGFR, Fms like tyrosine kinase 3, FLT3, inhibit, DCC2701, DCC-2701, DCC 2701, c-Met/HGFR, cMet, c-Met, cMet/HGFR, Cluster of differentiation antigen 135, CD135, Altiratinib
Field of Research
Cardiovascular Research, Signal Transduction
Purity
98.98% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.92 mM) ; DMSO:240 mg/mL (470.16 mM)
Smiles
Fc1ccc (NC (=O) C2 (CC2) C (=O) Nc2cc (F) c (Oc3ccnc (NC (=O) C4CC4) c3) cc2F) cc1
Molecular Formula
C26H21F3N4O4
Molecular Weight
510.46
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
V9683SAF-100UG 100 µg
Recombinant SMMHC Antibody / Smooth Muscle Myosin Heavy Chain
Sign In for Pricing
View Details